Erythropoietin with Iron Supplementation To Prevent Allogeneic Blood Transfusion in Total Hip Joint Arthroplasty
- 5 December 2000
- journal article
- clinical trial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 133 (11) , 845-854
- https://doi.org/10.7326/0003-4819-133-11-200012050-00008
Abstract
The optimum regimen of epoetin alfa for prevention of allogeneic blood transfusion is unknown. To determine whether a modified regimen of epoetin alfa reduces allogeneic blood transfusion in patients undergoing hip arthroplasty. Randomized, double-blind, multicenter trial comparing two modified dose regimens of epoetin alfa with placebo. 13 teaching hospitals and 4 community hospitals in Canada. 201 patients undergoing primary hip arthroplasty who had a hemoglobin concentration of 98 to 137 g/L and did not predonate blood. Patients were assigned in a 3:5:5 ratio to receive four weekly doses of epoetin alfa, 40 000 U (high-dose; n = 44) or 20 000 U (low-dose; n = 79), or placebo (n = 78), starting 4 weeks before surgery. All patients received oral iron supplementation, 450 mg/d, for 42 or more days before surgery. The primary end point was allogeneic transfusion. Secondary end points were thromboembolic events and change in reticulocyte count and hemoglobin concentration. Both modified epoetin alfa regimens significantly reduced the need for allogeneic transfusion: Five (11.4%) patients in the high-dose group (P = 0.001) and 18 (22. 8%) patients in the low-dose group (P = 0.003) had transfusion, compared with 35 (44.9%) patients in the placebo group. The hematologic response was substantial in patients who received epoetin alfa. In the high-dose group, low-dose group, and placebo group, the preoperative increase in reticulocyte count was 58.8, 37. 0 and 1.8 x 10(9) cells/L (P < 0.001), respectively, and the increase in hemoglobin concentration was 19.5, 17.2, and 1.2 g/L (P < 0.001). The incidence of thromboembolic events did not differ among groups. Both modified epoetin alfa regimens were effective compared with placebo in reducing allogeneic transfusion in patients undergoing hip arthroplasty. Patients who received high-dose epoetin alfa had the lowest transfusion rate.Keywords
This publication has 30 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects*Clinical Pharmacology & Therapeutics, 1998
- Preoperative Autologous Donation Decreases Allogeneic Transfusion but Increases Exposure to All Red Blood Cell TransfusionResults of a Meta-analysisArchives of internal medicine (1960), 1998
- Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: Preoperative strategies for avoiding allogeneic blood exposureThe American Journal of Surgery, 1995
- Allogeneic transfusion risks in the surgical patientThe American Journal of Surgery, 1995
- Color duplex Doppler ultrasound scanning for detection of deep venous thrombosis in total knee and hip arthroplasty patients: Incidence, location, and diagnostic accuracy compared with ascending venographyThe Journal of Arthroplasty, 1994
- Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietinThe Lancet, 1994
- Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: The importance of iron availability in optimizing responseThe American Journal of Medicine, 1994
- Effectiveness of perioperative recombinant human erythropoietin in elective hip replacementThe Lancet, 1993
- Perioperative asymptomatic venous thrombosis: Role of duplex scanning versus venographyJournal of Vascular Surgery, 1989
- Effect of oral iron therapy on the upper gastrointestinal tractDigestive Diseases and Sciences, 1988